Applicable groups of platinib and its therapeutic advantages

Platinib (trade name: Pujihua) is an oral, once-daily, powerful drug designed to inhibitRET. It has demonstrated outstanding results in the anti-cancer field and has been authorized by the China National Medical Products Administration for the treatment of a variety of cancers caused by RET gene mutations.

1. Applicable patient groups:

1. Platinib is specifically targeted atadult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for RET gene fusion.

2. For patients with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic treatment, whether they are adults or children aged 12 years and above, Platinib can provide a new treatment path.

3. This drug is also suitable for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic treatment and are unresponsive to radioactive iodine therapy (if radioactive iodine is applicable), covering adults and children over 12 years old.

2. Unique advantages:

1. Precise targeting: Platinib is known for its high selectivity and can accurately target theRET mutation in tumor cells, minimizing the impact on healthy cells, thereby reducing the risk of side effects.

2. Powerful efficacy: This drug performs well in inhibiting the growth and division of tumor cells driven by RET gene mutations, effectively controlling the disease process.

3. Improve quality of life: Compared with traditional chemotherapy, platinib can significantly reduce patients’ adverse reactions, thereby improving their overall quality of life.

In summary, platinib, as an innovative targeted therapy, has demonstrated its outstanding advantages in the treatment of cancers associated with RET gene mutations, bringing new treatment prospects to many patients. However, in order to ensure the safety and effectiveness of the treatment process, patients should still strictly follow medical instructions when using platinib and receive regular health monitoring.